Citigroup
CCCC icon

Citigroup’s C4 Therapeutics CCCC Stock Holding History

Citigroup’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-144,300
Closed -$519K – 5621
2024
Q4 		$519K Buy
144,300
+119,300
+477% +$593K ﹤0.01% 3798
2024
Q3 		$142K Buy
+25,000
New +$150K ﹤0.01% 4584

Other funds holding CCCC

Wasatch Advisors
Wasatch Advisors Salt Lake City, Utah $13.5B AUM 16.58% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Congress Asset Management
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.39% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
ALPS Advisors
ALPS Advisors Denver, Colorado $21.8B AUM 17.58% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Citigroup's CCCC Position: Q3 2026 in Review

Citigroup reduced its C4 Therapeutics (CCCC) stake by 73% in Q3 2026, selling an estimated $135K and leaving 13,207 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #4750.

Citigroup first reported a position in CCCC in Q4 2020 and has held it in 24 quarters since. The position peaked at $6.3M in Q1 2024. 38 funds tracked by Wall St. Rank hold CCCC as of Q3 2026.

  • Citigroup held 13,207 shares of C4 Therapeutics worth $44K as of Q3 2026.
  • Citigroup sold 36,182 C4 Therapeutics shares in Q3 2026, an estimated $135K.
  • C4 Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q3 2026, its #4750 holding.
  • Citigroup first reported a position in C4 Therapeutics in Q4 2020 and has held it in 24 quarters since.
  • Citigroup's C4 Therapeutics position peaked at $6.3M in Q1 2024.
  • 38 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2026.

Based on Citigroup's 13F filing for Q3 2026, filed 4 Nov 2026.